230 related articles for article (PubMed ID: 33863809)
21. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Falchook GS; Sachdev J; Imedio ER; Kumar S; Mugundu GM; Jenkins S; Chmielecki J; Jones S; Spigel DR; Johnson M
Invest New Drugs; 2023 Jun; 41(3):493-502. PubMed ID: 37171722
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E; Milosevic M; Corr B; Abbruzzese JL; Girda E; Miller RW; Croke J; Mackay H; Lee YC; Bowering V; Ramsahai J; Wang L; D'Souza A; Kunos CA; Oza AM; Lheureux S
Int J Gynecol Cancer; 2023 Aug; 33(8):1208-1214. PubMed ID: 37380217
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Chera BS; Sheth SH; Patel SA; Goldin D; Douglas KE; Green RL; Shen CJ; Gupta GP; Moore DT; Grilley Olson JE; Weiss JM
Cancer; 2021 Dec; 127(23):4447-4454. PubMed ID: 34379792
[TBL] [Abstract][Full Text] [Related]
24. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A; Kutzera J; Geenen JJ; Pluim D; Hofland I; Sanders J; Lopez-Yurda M; Beijnen JH; Huitema ADR; Witteveen PO; Steeghs N; van Haaften G; van Vugt MATM; de Ridder J; Opdam FL
Gynecol Oncol; 2023 Jul; 174():239-246. PubMed ID: 37236033
[TBL] [Abstract][Full Text] [Related]
25. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cole KA; Ijaz H; Surrey LF; Santi M; Liu X; Minard CG; Maris JM; Voss S; Reid JM; Fox E; Weigel BJ
Cancer; 2023 Jul; 129(14):2245-2255. PubMed ID: 37081608
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
[TBL] [Abstract][Full Text] [Related]
27. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
28. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
[TBL] [Abstract][Full Text] [Related]
29. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
30. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
31. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775.
Hauge S; Macurek L; Syljuåsen RG
Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845
[TBL] [Abstract][Full Text] [Related]
32. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
[TBL] [Abstract][Full Text] [Related]
33. A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.
Méndez E; Rodriguez CP; Kao MC; Raju S; Diab A; Harbison RA; Konnick EQ; Mugundu GM; Santana-Davila R; Martins R; Futran ND; Chow LQM
Clin Cancer Res; 2018 Jun; 24(12):2740-2748. PubMed ID: 29535125
[No Abstract] [Full Text] [Related]
34. Strategies for Targeted Therapy in Head and Neck Squamous Cell Carcinoma Using WEE1 Inhibitor AZD1775.
Kao M; Green C; Sidorova J; Méndez E
JAMA Otolaryngol Head Neck Surg; 2017 Jun; 143(6):631-633. PubMed ID: 28208168
[TBL] [Abstract][Full Text] [Related]
35. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Shafer D; Kagan AB; Rudek MA; Kmieciak M; Tombes MB; Shrader E; Bandyopadhyay D; Hudson D; Sankala H; Weir C; Lancet JE; Grant S
Cancer Chemother Pharmacol; 2023 Mar; 91(3):281-290. PubMed ID: 36864346
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of adavosertib therapy against anaplastic thyroid cancer.
Lu YL; Huang YT; Wu MH; Chou TC; J Wong R; Lin SF
Endocr Relat Cancer; 2021 Apr; 28(5):311-324. PubMed ID: 33769310
[TBL] [Abstract][Full Text] [Related]
38. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
40. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]